
WCLC 2018

Read the full Report (pdf)
IASLC World Conference on Lung Cancer 23-26 September 2018 Toronto, Canada
Featured articles


Interview with the IASCL President, Dr. Giorgio Scagliotti
CONTENTS
Online First
Presidential Symposium – Top 5 abstracts
Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer

Benefits of chest CT screening

New standard of care in extensive-stage small-cell lung cancer
No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype
New Aspects of Immunotherapy

Next generation immunotherapy in non-small-cell lung cancer
Combination therapies: Where are we in 2018?

Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer
New Aspects of Targeted Therapy

PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib


Mesothelioma

Unmet needs in surgical management of malignant pleural mesothelioma
Advanced Non-small Cell Lung Cancer

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer
Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer
Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer
Novel Therapies in ROS1 and EGFR
